[1]吴华国,张 慧.靶向survivin克服肿瘤耐药的研究进展[J].中国药理学通报,2018,(09):1189-1192.[doi:10.3969/j.issn.1001-1978.2018.09.002]
 WU Hua-guo,ZHANG Hui.New strategy for antagonizing drug resistance: targeting survivin[J].Chinese Pharmacological Bulletin,2018,(09):1189-1192.[doi:10.3969/j.issn.1001-1978.2018.09.002]





New strategy for antagonizing drug resistance: targeting survivin
吴华国1张 慧2
山东省肿瘤防治研究院1.头颈外科、2.肿瘤内科,山东 济南 250117
WU Hua-guo1 ZHANG Hui2
1.Dept of Head and Neck Surgery; 2.Dept of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan 250117, China
肿瘤 化疗 多药耐药 survivin 凋亡抑制蛋白家族 靶向
tumor chemotherapy multidrug resistance survivin inhibitor of apoptosis proteins(IAP)family targeting
R-05; R341; R329.25; R730.5; R977.6
Multidrug resistance(MDR)often leads to failure of cancer chemotherapy. survivin, a member of the inhibitor of apoptosis proteins(IAP)family, is overexpressed in almost all kinds of tumor cells. Importantly, survivin has been identified as one of the most important molecules involved in the regulation of MDR. Therefore, inhibiting the activity of survivin or down-regulating the expression of survivin might be an effective strategy to overcome tumor MDR. In this article, the roles of survivin involved in the development of drug resistance and the strategies to overcome drug resistance by targeting survivin are thus reviewed.


[1] Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997, 3(8): 917-21.
[2] Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy[J]. Int J Mol Sci, 2014, 15(2): 2494-516.
[3] Jutzy J M, Khan S, Asuncion-Valenzuela M M, et al. Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro[J]. Cancer Microenviron, 2013, 6(1): 57-68.
[4] Roy K, Kanwar R K, Krishnakumar S, et al. Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model[J]. Int J Nanomedicine, 2015, 10: 1019-43.
[5] Salzano G, Navarro G, Trivedi M S, et al. Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J]. Mol Cancer Ther, 2015, 14(4): 1075-84.
[6] Caldas H, Jiang Y, Holloway M P, et al. Survivin splice variants regulate the balance between proliferation and cell death[J]. Oncogene, 2005, 24(12): 1994-2007.
[7] Hu D, Liu S, Shi L, et al. Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein(XIAP)complex to free caspase activity leading to cytolysis of target tumor cells[J]. J Biol Chem, 2010, 285(24): 18326-35.
[8] Chettiar S N, Cooley J V, Park I H, et al. Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle[J]. Bioorg Med Chem Lett, 2013, 23(19): 5429-33.
[9] Altieri D C. Survivin, versatile modulation of cell division and apoptosis in cancer[J]. Oncogene, 2003, 22(53): 8581-9.
[10] Takeno S, Yamashita S, Takahashi Y, et al. Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression[J]. Eur J Cardiothorac Surg, 2010, 37(2): 440-5.
[11] Bhanot U, Heydrich R, Moller P, et al. survivin expression in pancreatic intraepithelial neoplasia(PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma[J]. Am J Surg Pathol, 2006, 30(6): 754-9.
[12] 谷满仓,钱亚芳,孙 悦,等. 薏苡仁脂调控凋亡相关蛋白Bax、Bcl-2及survivin增强胰腺癌细胞对吉西他滨敏感性的研究[J]. 中国药理学通报, 2013, 29(4): 491-5.
[12] Gu M C,Qian Y F, Sun Y,et al. Coix seed lipids sensitize the activity of gemcitabine against pancreatic cancer cells through modulating Bax, Bcl-2 and survivin[J]. Chin Pharmacol Bull,2013, 29(4): 491-5.
[13] Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis[J]. Cancer, 2001, 91(11): 2026-32.
[14] Fukuda S, Pelus L M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+)cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis[J]. Blood, 2001, 98(7): 2091-100.
[15] Liu J L, Wang Y, Jiang J, et al. Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA[J]. Chin Med J(Engl), 2010, 123(20): 2901-7.
[16] Tran J, Master Z, Yu J L, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF[J]. Proc Natl Acad Sci USA, 2002, 99(7): 4349-54.
[17] Tsubaki M, Takeda T, Ogawa N, et al. Overexpression of survivin via activation of ERK1/2, Akt, and NF-kappaB plays a central role in vincristine resistance in multiple myeloma cells[J]. Leuk Res, 2015, 39(4): 445-52.
[18] Bhattacharyya J, Mihara K, Ohtsubo M, et al. Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression[J]. Cancer Sci, 2012, 103(1): 34-41.
[19] Nestal D M G, Silva K L, Vasconcelos F C, et al. survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells[J]. Oncol Rep, 2011,25(6): 1613-9.
[20] Singh N, Krishnakumar S, Kanwar R K, et al. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers[J]. Drug Discov Today,2015, 20(5): 578-87.
[21] Imai Y, Yamagishi H, Ono Y, et al. Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells[J]. Clin Transl Med, 2012, 1(1): 24.
[22] El D N, Abdelzaher E. Stem cell markers OCT4 and nestin in laryngeal squamous cell carcinoma and their relation to survivin expression[J]. Pathol Res Pract, 2014, 210(11): 751-8.
[23] Feng R, Dong L. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells[J]. Int J Clin Exp Pathol, 2015, 8(6): 6107-16.
[24] Hilovska L, Jendzelovsky R, Jendzelovska Z, et al. Downregulation of BCRP and anti-apoptotic proteins by proadifen(SKF-525A)is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells[J]. Int J Oncol, 2015, 47(4): 1572-84.
[25] Hofmann U B, Voigt H, Andersen M H, et al. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes[J]. Eur J Immunol, 2009, 39(5): 1419-24.


 LIU Hong chun,DU Xiao guang,GENG Mei yu.New advances in isoformselective inhibitors of Zn2+dependent histone deacetylase[J].Chinese Pharmacological Bulletin,2010,(09):0.
 DONG Xian zhe,ZHANG Peng,BI Ming gang.Research progress on serine/threonine kinase PLK1[J].Chinese Pharmacological Bulletin,2010,(09):289.
 HU Shi lian.Melatonin in the treatment of cancer and its mechanism[J].Chinese Pharmacological Bulletin,2008,(09):0.
 LI De guan,MENG Ai min.Hematopoietic stem cell senescence[J].Chinese Pharmacological Bulletin,2008,(09):0.
 LIU Xin yan,YU Qing sheng,YU Hong e,et al.China cobra venom active factor can induce apoptosis of endothelial cells[J].Chinese Pharmacological Bulletin,2008,(09):0.
 ZHANG Zu bin,GU Zhen lun,JIANG Xiao gang.The role of miRNAs in the tumor and tumor stem cells[J].Chinese Pharmacological Bulletin,2009,(09):0.
 LI Li,LI Jing,GENG Mei yu.The role of protein kinase C in cancer and the progress of inhibitors targeting protein kinase C[J].Chinese Pharmacological Bulletin,2009,(09):0.
 LIU Ping,LI Jing.The effects of Metacycloprodigiosin on tumor metastasisassociated cell behavior in vitro[J].Chinese Pharmacological Bulletin,2010,(09):501.
 ZHANG Yan,XIAO Ting ting,SHEN Xiang chun.The advance role and pharmacological effects of metallothionein[J].Chinese Pharmacological Bulletin,2010,(09):821.


基因项目:自然科学基金资助项目(No 8150111724); 山东省博士基金资助项目(No 2015BSC03007); 山东省医科院基金资助项目(No 2014-42)
作者简介:吴华国(1990-),男,硕士,住院医师,研究方向:肿瘤药理学,E-mail whg2007@aliyun.com;
张 慧(1986-),女,博士,主治医师,硕士生导师,研究方向:肿瘤个体化治疗,通讯作者,Tel:0531-67626912,E-mail:hui8942615@163.com
更新日期/Last Update: 2018-08-26